Secteur: MedTech

MedTech

Cryoblood

Blood cellscryoconservationDirected freezing

Non-toxic directional cryopreservation method

Download the technology sheet

Ref. No.: MA00606

Summary

Karim Ghoufiri

Business Developer

TECHNOLOGY

  • Non-toxic cryopreservation method (previously described directional freezing platfrom) for cells freely suspended in an isotonic aqueous solution, employing a novel directed freezing approach that eliminates the need for conventional cryoprotectants.

MARKET

  • Suggested applications : medical biobanks, cell therapy, cell line developers, Assisted Reproductive Technology (ART), academic research
  • Competitive advantages : non-toxic, simplifying the cryopreservation value chain, less costly than traditional methods, no need for the cryoprotectant washing step

DEVELOPMENT STATUS

  • Proof of concept on red blood cells: demonstration of esterase activity (viability); after storage for more than 100 days at -80 °C:
    • 95% at sub-physiological concentrations
    • 80% at physiological concentrations
  • Proof of concept on nucleated cells (mouse and human fibroblasts)
  • Ongoing maturation program: (i) development of a prototype capable of controlling freezing in commercial bags, (ii) scale-up of the directional freezing device, (iii) functional tests on cells of interest after freezing/thawing, and (iv) long-term storage and transport.

IP

  • Patent application filed on March 22, 2022
  • Publication number : WO2023180635
  • National/regional phase : Australia, Canada, United-States, Israel, Japan, Europe.

VALORISATION STRATEGY

  • Licensing
MedTech

Tabullaria

MaterialsmedtechProsthesis

Baromorphic sleeve that adapts to stump volume variations

Download the technology sheet

Ref. No.: MA00657

Summary

Alexis Maloux

Business developper

Technology

  • Device based on new materials to make tibial prostheses more comfortable.
  • Better adaptation of the socket to the residual limb by conforming to its volume variations, thus allowing a better fit and therefore improved comfort.
  • The technology can be adapted to any stump shape and any prosthesis attachment system.
  • Real-time adaptation to volume variations for better pressure distribution and vascularization.
  • Reduction of shocks, vibrations, and pistoning effects.
  • Ease of production (industrial series or custom-made).

 

Market

  • Every year, thousands of people undergo lower limb amputation as a result of trauma, cancer, or diabetes. The stump often remains sensitive, and wearing a prosthesis is often uncomfortable or painful.
  • The mechanical discomfort caused by pistoning effects can be reduced with a sock and a suitable prosthesis retention mechanism, but this solution is unsuitable for pain related to changes in stump volume. These volume changes can be caused by temperature variations, vasodilation, physical activity, etc., and the sockets are not flexible enough to adapt to them.

 

Development

  • Device development: 3D printing and integration into a silicone socket.
  • Real-life evaluation: tested on an amputee for 24 hours.

 

IP

  • Asset currently being established

 

Valorisation strategy

  • Co-development
  • Licensing
MedTech
Digital and engineering

MITools

DiagnosisDiagnosticEEGSLASoftware

Modulation Index Tools Software: Software for analysing biomarkers of cortical dysfunction in neurological diseases.

Download the technology sheet

Ref. No.: MA00714

Summary

Othman Guenoun

Business developper

Technology

  • Tool for analysing biomarkers of cortical dysfunction in neurological diseases. The tool works by post-acquisition of EEG signals.
  • This solution contributes to the early identification of neurodegenerative diseases:
    • The software acquires raw EEG signals and removes artefacts such as body or eye movements, based on the assessment of the technician/doctor and with the help of a visual ICA (Independent Component Analysis) tool, all via a user-friendly interface that allows results to be interpreted as quickly as possible.
    • After processing these EEGs, the software should be able to provide an early diagnosis of a neurodegenerative disease using an associated biomarker. The first target is Charcot’s disease, but it could also be applied to Parkinson’s or Alzheimer’s disease.

 

Market

  • The growing prevalence of diseases such as epilepsy, sleep disorders and other neurological conditions is driving demand for advanced EEG analysis tools.
  • With an ageing population and the increasing prevalence of neurodegenerative diseases, demand for early diagnosis tools is expected to continue to grow.
  • Research into neurodegenerative diseases such as Charcot’s disease, Alzheimer’s, Parkinson’s and Huntington’s is struggling to develop curative treatments.

 

  • Applications:
    • Early diagnosis of neurodegenerative diseases
    • Applied research
    • Clinical trials
    • Clinical routine for patient assessment and follow-up

 

Development

  • EEG signal acquisition and processing
  • User interface and functional network architecture
  • User guide created

 

In development:

  • New version including polysomnography
  • Working with a cohort to identify biomarker threshold values
  • Integration of AI building blocks

 

IP

  • Software filed march 2024

 

Valorisation strategy

  • Licensing or codevelopment
MedTech

InjectCell

AMDCell therapyGlaucoma

Retinal injection for cell therapy

Download the technology sheet

Ref. No.: MA00514

Summary

Othman Guenoun

Business developer

Technology

  • A device that allows soft tissue (agar plates, cell sheets) to be injected through a minimal subretinal incision.
  • This instrument greatly reduces invasiveness and allows for maximum preservation of retinal structures.
  • The implant is ‘loaded’ into a catheter using a first injector (winder), which then allows the implant to be injected subretinally.
  • The device can also be used to implant flexible biological or artificial tissue into or under living organs. This flexible tissue contains cells capable of rebuilding cells in a diseased organ or prosthesis in order to restore its functionality, or any other substrate and content.
  • This medical device consists of three parts:

1) A removable cartridge with a receptacle and a cannula designed to receive, package and guide the soft tissue. (Fig. 1)

2) A first pushing device for transferring the flexible tissue from the receptacle to the cannula when the injection cartridge is attached to this first pushing device. (Fig. 2)

3) A second pushing device adapted to transfer the flexible tissue from the cannula to the organ when the injection cartridge is attached to this second pushing device. (Fig. 3)

 

Market

  • The ophthalmic treatment market is expected to reach $17.5 billion for retinitis pigmentosa by 2029 and $36 billion for AMD by 2032.
  • Current subretinal implantation methods, which cause significant damage to the retina, combined with the increase in eye diseases, are creating strong demand for innovative surgical solutions.

 

Development

  • In vitro (pig eyes) and in vivo (dogs and macaques) results for the implantation of a layer of retinal pigment epithelium
  • Ergonomic testing in the laboratory
  • Functional prototype

 

IP

  • PCT Patent application filed
  • September 2024 – PCT/IB2024/000546

 

Valorisation strategy

  • Licensing

 

MedTech

COVEM

algorithmBiomarkerBiomarqueurDétectionDiagnosisdyspnea

Multifactor detection of respiratory disorders

Download the technology sheet

Ref. No.: MA00595

Summary

Karim Ghoufiri

Business developper

Technology

  • Device aggregating multimodal signals (ECG, EEG, movement, respiratory rate, etc.) to detect a change in the patient’s respiratory status. In the event of dyspnea :
    • Automatic modification of respiratory system parameters
    • Alert to medical staff
  • Version with camera to detect facial tics signs of respiratory discomfort + thermal camera to detect respiratory frequency.

 

Market

  • Applications: Dyspnea detection, in hospital and at home, based on the signals captured, Improved respiratory equipment
  • 65% of inpatients and over 90% of post-ICU patients are monitored manually, not continuously.
  • Spot checks at 4-8 hour intervals: changes in vital signs are not detected.
  • 50-70% of cases of patient deterioration can be predicted hours before they occur.
  • Respiratory rate is the highest-ranking variable in predictive models.
  • 60% of patients on home non-invasive ventilation (NIV) are thought to be poorly ventilated.
  • The sensors integrated into current ventilators are not sufficiently accurate or effective in detecting respiratory disorders.

 

IP

  • 4 patent families
    • 2012 FR1254089 – granted CA, EP, JP, US, FR
    • 2021 PCT/FR2021/051756 – pending EP, US
    • 2022 EP21306638.4 – pending EP, US
    • 2023 PCT/IB2023/00028 – pending EP, US

 

Development

  • 10 years of research (AP-HP Sorbonne Université CNRS)
  • Prototype under development

 

Valorisation strategy

  • Licensing
MedTech

Fibula

BiomimetismmedtechProsthesis

Modular bioinspired tibial prosthesis

Download the technology sheet

Ref. No.: MA00660

Summary

Alexis Maloux

Business developper

Technology

  • Modular tibial prosthesis, comprising a stem and a ground support block, both connected to each other by a means of connection. This confirmation provid amputees with a biomechanical, ergonomic leg that functions as closely as possible to human walking.
  • Easy assembly/disassembly . This makes it possible to generate ranges of parts to meet the changing physical activities and morphologies of wearers (has to be done by a professional)
  • It is also possible to adapt the tibial prosthesis to a patient thanks to its modularity. This makes the invention more readily accessible and adaptable.

 

Market

  • Growth of +5-6%/year in the prosthetics market (diabetes is the leading cause of lower limb amputation).
  • ~ 120k amputees in France, half of whom are below the knee.
  • 12k transtibial amputations per year in France.125k per year in the United States, 230k in Europe, 900k worldwide.
  • Various uses for prostheses: need for modularity.
  • Current tibial prostheses generally feature a prosthetic foot extended by a simple tube attached to the patient’s knee in a single piece, with the various components of the same prosthesis all fixed together. As a result, as soon as one part of the prosthesis is damaged, the entire prosthesis has to be replaced

 

Development status

  • Design and assembly: development of a modular tibial prosthesis (shaft + ground support block connected by a linkage system), with material selection and validation.
  • Experimental evaluation: kinematic tests carried out by the UTEAM team (UTC), confirming functionality for walking, with recommendations on the materials used.

 

IP

  • Two patent applications ongoing:
    • FR2313929 filed on 11/12/2023
    • WO2025/125112 filed on 11/12/2024

 

Valorisation strategy

  • Co-development
  • Licensing
MedTech

Chronos

DiagnosticHD-EMG gridMuscle health

New HD-EMGs grid for assessing muscle health

Download the technology sheet

Ref. No.: MA00710

Summary

Karim Ghoufiri

Business developper

Technology

  • Novel HD-EMG grid design that integrates with an existing hardware technology (e.g. the MOBITA device developed by TMSI) for assessing muscle health.
  • The CHRONOS project aims to design a new ambulatory device for measuring (hardware) and analyzing (AI-based software) HD-EMG signals. This device will be sustainable, robust, effective, less expensive, and adaptable to various clinical situations as well as the general public.

Market

  • Suggested applications : detect early aging (healthy subjects), detect sarcopenia (pathological subjects), evaluate functional recovery post-hip prosthesis placement.

IP

  • PCT patent application filed on Dec. 27, 2024 (PCT/FR2024/051778)

Development status

  • In vivo results : findings from subjects demonstrating the superiority of this technology compared to conventional EMG recordings.

Valorisation strategy

  • Startup
MedTech

PRLens

AMDLensesZonePRL

Contact lenses for AMD

Download the technology sheet

Ref. No.: MA00674

Summary

Karim Ghoufiri

Business developper

Technology

  • The project developers have devised a groundbreaking technology involving the integration of a prism into a contact lens. This innovative approach aims to deviate the optical axis, presenting a novel avenue in treating conditions like macular degeneration. By retraining patients to realign their gaze effortlessly, this innovation seeks to minimize ocular fatigue while also serving a preventative purpose.

 

Market

  • The technology is intended for both Dry Age-Related Macular Degeneration (AMD) and Wet Age-Related Macular Degeneration (AMD).

 

Development status

  • At the moment, there are ongoing studies focusing on the localization of the intact zones within the retina. The prototype’s design does not exist and there’s a need to validate certain characteristics before finalization

 

IP

  • Patent pending PCT
    • IB2024/000068 – 2024/02/13
    • First positive written opinion issued by the EPO

 

Valorisation strategy

  • Licensing
MedTech

Biofilm

AntibiorésistanceBiofilmUltrasound

Ultrasound-based solution to combat antibiotic resistance

Download the technology sheet

Ref. No.: MA00718

Summary

Karim Ghoufiri

Business developper

Technology

  • One of the mechanisms of antibiotic resistance is the formation of a biofilm that protects bacteria.
  • The aim of the invention is to facilitate the passage of antibiotics without destroying the biofilm by applying ultrasound.

 

Bacterial colonies with (A) and without ultrasound (B)

 

Market

  • This approach could help combat nosocomial infections, particularly after the placement of implants such as hip or knee replacements. In 8% of implant surgeries, bacteria form a biofilm; currently, the only alternative is to remove the implant and wait several months before placing a new one. With this invention, it would be possible to treat the biofilm.
  • Biofilms are thought to be responsible for 65% to 75% of nosocomial infections.

 

Development status

  • TRL 3 (successful PoC on a biofilm model (E. Coli) in an alginate gel)

 

IP

  • PCT patent application filed on December 20, 2024.

 

Valorisation strategy

  • Co-development

 

 

MedTech

Mimetube

3D cell cultureBiomaterialsTissue regeneration

Creation of 3D Collagen Microtubes with Modular Properties

Download the technology sheet

Ref. No.: MA00690

Summary

Alexis Maloux

Business Developer

Technology

  • New macroporous biomaterials that mimic native tissues, thanks to an innovative process: topotactic fibrillogenesis of collagen I + ice templating.
  • A process that is easy to industrialize by adjusting the parameters to obtain complex shaped materials with properties that can be modulated according to the area to be reconstructed.
  • These materials have been shown to regenerate a wide range of soft tissues (muscles, tendons, ligaments, nerves, etc.)
  • Current material production speed: 10mm per minute.

 

Market

  • First application in vascular and thoracic surgery, to facilitate grafting of small-diameter arteries, and upper airway repair.
  • Second application to enhance 3D cell culture models, for drug screening.

 

Development status

  • Development of the protocol for freezing and topotactic fibrillogenesis in the gas phase and then in the liquid phase.
  • Development of double-layer materials
  • Demonstration of the functionalization of materials (4mm internal diameter, 2mm thickness – cell colonization within a few days) & successful leak testing)
  • In vivo implantation in mice for applications as muscle grafts.
  • Development of double-layer materials of a size compatible with tracheal implantation (diameter 21 mm, thickness 4.25 mm) – Implantation in sheep on going

 

IP

  • A patent application filed in 2023
  • PCT/IB2023/000465

 

Valorisation strategy

  • Co-development
  • Licensing